DIA Biosimilars 2013

Awards & Advancement

Dendreon names Fenton to board of directors

Tuesday, November 8, 2011 10:12 AM

Dendreon has named Dennis M. Fenton to the board of directors, effective November 8, 2011.

More... »

Cenduit: Now with Patient Reminders

Advanced Clinical names director of clinical operations

Monday, November 7, 2011 11:19 AM
Advanced Clinical has named Michaelene Lewand director of clinical operations to lead its expansion of service offerings.

More... »

CRF Health – eCOA Forum

Crane joins SNBL USA

Monday, November 7, 2011 10:47 AM
SNBL USA has named Mark T. Crane vice president of business development. Crane will have overall responsibility for the company’s marketing, sales and business development efforts and will be tasked with driving the growth of SNBL USA's business model and fostering positive relationships with new and current customers.

More... »

ICON named clinical research team of the year

Monday, November 7, 2011 10:10 AM

ICON has won the clinical research team of the year award at the annual 2011 Scrip Awards.

More... »

NanoString raises $20 million in Series D financing

Monday, November 7, 2011 09:52 AM

NanoString Technologies, a privately held provider of life science tools for translational research and developer of molecular diagnostics, has closed $20 million in a Series D round of equity financing. New investors include GE, BioMed Ventures and Henri Termeer, former chairman and CEO of Genzyme. All previous venture investors in NanoString also participated in the financing, including Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

More... »

Scrip names PPD best CRO

Friday, November 4, 2011 11:43 AM
PPD has been named the best contract research organization by Scrip Intelligence, which also has honored PPD for deploying the best technological development in clinical trials.

More... »

Quin joins Asymchem as VP, medicinal chemistry

Thursday, November 3, 2011 01:31 PM

Asymchem Life Science has named Dr. Li Qun vice president of medicinal chemistry. His responsibilities include managing FTE work in medicinal and preclinical synthetic chemistry, based out of TEDA Tianjin.

More... »

H3 Biomedicine names CEO

Thursday, November 3, 2011 10:27 AM

H3 Biomedicine has named Markus Warmuth, M.D., president and chief executive officer, effective immediately.

More... »

Tetlow joins Pathwork as CFO

Thursday, November 3, 2011 09:44 AM

Pathwork Diagnostics has named Sharon Tetlow chief financial officer.

More... »

Karyopharm Therapeutics secures $10 million in Seires A2 financing

Wednesday, November 2, 2011 01:29 PM

Karyopharm Therapeutics has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione. This brings the total raised by the company to approximately $32M since its inception. The funds will be used to expand the planned phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export (SINE) for various cancers. The company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs